Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema
NCT04387604
·
clinicaltrials.gov ↗
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Diabetic Macular Edema
Interventions
DRUG:
Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
Sponsor
Centro Hospitalar do Porto